Related Experiment Video
Updated: Mar 24, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Correlation analysis of coagulation factor level and chronic low-grade inflammation in patients with type 2 diabetes
Li Weng1, Yan Wang1, Dejuan Li2
1Department of Endocrinology, People's Hospital of Qijiang District, Chongqing, China.
Objectives:
To analyze differences in coagulation function and plasma inflammatory factors between type 2 diabetes mellitus (T2DM) patients with and without ischemic stroke (IS), and explore related mechanisms.
Methods:
50 patients with T2DM complicated with IS (experimental group, EG) and 50 patients with simple T2DM (control group, CG) were retrospectively included, while 30 healthy volunteers served as the blank group (BG). The expression levels of plasma interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and nuclear factor-κB (NF-κB) in the EG were significantly elevated as against the CG and the BG (p<0.05).
Results:
As against the CG and the BG, activated partial thromboplastin time (APTT) and prothrombin time (PT) levels were significantly reduced, while the plasma fibrinogen (FIB) and D-Dimer (DD) levels were significantly elevated in the EG; The incidence of postoperative complications in the EG (13.46 %) was significantly reduced as against the CG (21.15 %) (p<0.05). IL-6 was notably negatively correlated with APTT (p=0.002, r=-0.432); it was extremely significantly negatively correlated with PT (p=0.000, r=-0.536); it was notably positively correlated with plasma FIB content (p=0.001, r=0.445).
Conclusions:
The coagulation function and peripheral blood inflammatory markers in patients with T2DM complicated by IS were significantly different compared to those in patients with T2DM alone and healthy volunteers. The correlation between inflammatory markers and coagulation indicators (e.g., the negative correlation between IL-6 and APTT/PT) identified in this study holds important clinical significance. It provides new insights for thrombosis risk stratification and personalized antithrombotic treatment in T2DM patients. Monitoring the levels of inflammatory markers may optimize thrombosis prevention strategies and enhance the precision of clinical diagnosis and treatment.
More Related Videos
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Coronary Artery Disease I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Acute Coronary Syndrome III: Diagnostic Studies